Universitätsklinikum Gießen und Marburg, Klinik für Gynäkologie, gyn. Endokrinologie und Onkologie
„Compliance and Efficacy of Ibandronate 3 mg iv Quaterly vs. Oral Alendronate Real World Data with the Non-interventional Study VIVA“
Dr. med. Christina Kliebe
Numerous clinical trials have demonstrated the efficacy of Bisphosphonates in the treatment of postmenopausal osteoporosis. Bisphosphonates have been shown to be an effective treatment with regard to risk reduction of bone loss, osteoporosis related fractures, bone pain and as such are currently the standard of care treatment. However, the translation of clinical study results to real world experience is dependent on treatment compliance which in RCTs is generally high while in clinical practice significantly lower. This is generally true for many chronic diseases where patient adherence to treatment has been shown to be poor, which is particularly the case for oral bisphosphonates. Oral formulations of bisphosphonates are associated with poor gastrointestinal absorption, an increase in gastrointestinal adverse events necessitating complicated dosing regimens. It is well known that suboptimal adherence to bisphosphonate therapy is associated with an increased risk of fracture. In contrast to the poor adherence with oral bisphosphonates, the treatment with Ibandronate iv seem to guarantee an optimal absorption and adherence, because it is applied directly by the physician.